Neurotech International (ASX: $NTI) Q3 FY24 Activities Report

Neurotech International Limited (ASX: $NTI) has released its activities report for the quarter ended 31 March 2024, showcasing significant progress in extending clinical trials for paediatric neurological disorders. The company reported positive results from the Phase II/III ASD clinical trial and the Phase I/II Rett Syndrome clinical trial. Additionally, Neurotech announced a $10.0 million capital raise to further its clinical and commercial development pathways.

Executive Commentary on Clinical Trials and Capital Raise

Professor Michael Fahey, Chief Investigator of the NT1164 Phase I/II Trial, expressed delight with the progress of patients under the long-term extension to the original clinical trials. He emphasized the significant clinical improvements observed in patients and the strong desire of caregivers to continue treatment over the long term. The positive results from the Phase II/III ASD clinical trial and the Phase I/II Rett Syndrome clinical trial demonstrate the potential of NT1164 in addressing the substantial unmet market need for safe and effective therapies for autism and Rett Syndrome. The $10.0 million capital raise will be instrumental in accelerating registration-directed activities, funding further clinical trials, and expanding manufacturing.

Outlook and Corporate Activity

Neurotech's outlook for the remainder of FY24 includes the release of full data from the Rett Syndrome Phase I/II Clinical Trial, meeting outcomes for TGA Regulatory Advice, and publications for ASD Phase I/II + pre-clinical NT1164 results. The company also anticipates the availability of metabologenomic data from the Phase I/II PANDAS/PANS Clinical Trial. Furthermore, Neurotech's ESG Report reflects its commitment to integrating ESG considerations into its operations for long-term success and sustainability. The $10.0 million capital raise is expected to support the company's ambitions in accelerating the use of NT1164 in addressing paediatric neurological disorders and expanding its clinical and commercial development pathways.